Clinical trials: Cardiomyopathy, Congestive
Dilated Cardiomyopathy, Lamin A/C Gene Mutation
A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation
This is a randomized, double-blind, placebo-controlled study in patients with dilated cardiomyopathy (DCM) due to a mutation of the gene encoding the lamin A/C protein (LMNA).
- Trial name
- REALM-DCM (NCT03439514)
- Testing
- ARRY-371797 (PF-07265803)
- Where
- 107 sites in United States, Argentina and 8 more
- Volunteers
- 77 people
- Sponsor
- Pfizer
Sudden Cardiac Death, Arrhythmias
Genetic Risk Assessment of Defibrillator Events
Arrhythmias remain a major health problem, causing at least 250,000 deaths annually in the United States. Pharmacological treatments often do more harm than good, and device therapies are limited by high cost and effects on…
- Conditions
- Sudden Cardiac Death, Arrhythmias, Congestive Heart Failure, Cardiomyopathy
- Trial name
- GRADE (NCT02045043)
- Where
- 6 sites in United States
- Volunteers
- 1,807 people
- Sponsor
- University of Iowa
Pediatric Dilated Cardiomyopathy
Potential Role of Water-soluble Ubiquinol in Complementary Therapy for Pediatric Dilated Cardiomyopathy
Pediatric dilated cardiomyopathy (PDCM) is the most common form fond in children. Water-soluble coenzyme Q10 (ubiquinol) is better absorbed than lipid-soluble coenzyme Q10 (ubiquinone) and is directly involved in the antioxidant…
- Trial name
- NCT02847585
- Testing
- Water-soluble Ubiquinol
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- Chung Shan Medical University
Heart Failure With Reduced Ejection Fraction, Dilated Cardiomyopathy
v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491
The purpose of this Phase 1b/2a study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MYK-491 in patients with stable heart failure.
- Trial name
- NCT03447990
- Testing
- MYK-491
- Where
- 17 sites in United States, France and 5 more
- Volunteers
- 52 people
- Sponsor
- Bristol-Myers Squibb
Congestive Heart Failure, Cardiomyopathy
Cardiac Hormone Replacement With Brain Natriuretic Peptide (BNP) in Heart Failure
The purpose of this study is to determine the effects of subcutaneous injection of Human BNP (nesiritide), a hormone produced by the heart, on the pumping ability of the heart, kidney function, and hormonal function in persons…
- Trial name
- SubqBNP (NCT00252187)
- Testing
- B-type Natriuretic Peptide (BNP)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Horng Chen
Dilated Cardiomyopathy (DCM)
Evaluating the Prognostic Impact of Anti-β1AR Antibodies and Anti-L-CaC Antibodies in Patients With Dilated Cardiomyopathy
Background of the study The etiology of dilated cardiomyopathy (DCM) is complex and involves a variety of genetic, environmental, and immunologic factors.
- Trial name
- NCT06741995
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Dilated Cardiomyopathy, Obstructive Sleep Apnea
Continues Positive Airway Pressure Treatment for Patients With Dilated Cardiomyopathy and Obstructive Sleep Apnea
The aim of this randomized controlled study is to investigate the effect of continues positive airway pressure (CPAP) treatment in patients with dilated cardiomyopathy (DCM) and concomitant obstructive sleep apnea (OSA).
- Trial name
- RIDA (NCT02989181)
- Testing
- Continues Positive Airway Pressure (CPAP)
- Where
- Sweden
- Volunteers
- 44 people
- Sponsor
- Göteborg University
Cardiomyopathies, Heart Failure, Congestive
A Study of Short-Term Outcomes and Economic Impact For Patients With Worsening Congestive Heart Failure When Natrecor (Nesiritide) is Added to Standard-Care Therapy, Compared to Administration of Placebo With Standard-Care Therapy
The purpose of this pilot study is to compare the clinical effects, safety profile, and economic impact of standard therapy plus Natrecor® (nesiritide, a recombinant form of the natural human peptide normally secreted by the…
- Conditions
- Cardiomyopathies, Heart Failure, Congestive, Dyspnea, Paroxysma
- Trial name
- NCT00270387
- Testing
- Natrecor (nesiritide)
- Volunteers
- 250 people
- Sponsor
- Scios, Inc.
Shock, Sepsis
Hemodynamic Evaluation of Preload Responsiveness in Children by Using PiCCO
The purpose of this study is To assess the value of dynamics (SVV, PPV) and static indices (GEDVI, ITBVI, CVP) of preload and its combination with contractility (CI,SV, ventricular power, dP/dtmax, CFI, GEF) and lung water…
- Conditions
- Shock, Sepsis, Systemic Inflammatory Response Syndrome, Low Cardiac Output
- Trial name
- PreloaDren (NCT01157299)
- Where
- 7 sites in Spain
- Volunteers
- 100 people
- Sponsor
- Hospital Universitario La Paz
Ischemic Cardiomyopathy, Dilated Cardiomyopathy
Manganese-Enhanced Magnetic Resonance Imaging of the Myocardium
Scanning the heart using magnetic resonance imaging (MRI) enables detailed assessment of its structure and function. MRI can give more detailed information about the heart by using a contrast 'dye' that is injected into a vein…
- Conditions
- Ischemic Cardiomyopathy, Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy
- Trial name
- NCT03607669
- Testing
- Mangafodipir trisodium
- Where
- United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)
IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches
The goal of this clinical trial is to learn which iron treatment works better for adults with congestive heart failure and low iron levels: intravenous (IV) iron given through a vein or oral (PO) iron taken by mouth.
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF), Iron Deficiency
- Trial name
- IRONICA (NCT07053475)
- Testing
- Ferric Carboxymaltose, Ferrous Sulfate
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Syed Hamza Mufarrih
Coronary Artery Disease, Congestive Heart Failure
Cardiac Stem Cell Infusion in Patients With Ischemic CardiOmyopathy (SCIPIO)
The purpose of this study is to investigate the safety of intracoronary cardiac stem cells (CSCs) therapy in humans. Currently, there is no effective intervention to regenerate (regrow) dead heart muscle after a heart attack.
- Trial name
- SCIPIO (NCT00474461)
- Testing
- Treatment group
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Louisville
Heart Failure, Congestive
FUSION I Assesses Safety and Tolerability of Two Doses of NATRECOR (Nesiritide) Administered to Patients With Worsening Congestive (Decompensated) Heart Failure Who Are Concurrently Receiving Their Usual Cardiac Medications and Are at High Risk for Hospitalization.
The purpose of this study is to assess the safety and tolerability of two doses of nesiritide (a recombinant form of the natural human peptide normally secreted by the heart in response to heart failure) when administered…
- Trial name
- NCT00270361
- Testing
- nesiritide, usual long term cardiac medications
- Volunteers
- 214 people
- Sponsor
- Scios, Inc.
Peripheral Artery Disease, Coronary Disease
Evaluation of Patients With Known or Suspected Heart Disease
In this study researchers will admit and evaluate patients with known or suspected heart disease referred to the Cardiology Branch of the National Heart, Lung, and Blood Institute (NHLBI).
- Conditions
- Peripheral Artery Disease, Coronary Disease, Diabetes and Heart Failure, Dilated Cardiomyopathy
- Trial name
- NCT00001313
- Where
- 2 sites in United States
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Duchenne Muscular Dystrophy, Duchenne Muscular Dystrophy-Associated Dilated Cardiomyopathy
Duchenne Muscular Dystrophy Heart Study
Retrospective cohort study including patients with genetically proven Duchenne muscular dystrophy, diagnosed from January 1993 to March 2020.
- Trial name
- DMD-HS (NCT03443115)
- Where
- France
- Volunteers
- 700 people
- Sponsor
- Hôpital Cochin
Cardiomyopathy
AI-SCREENDCM Decentralized Clinical Trial - Pilot Study
The purpose of this study is to assess the feasibility and impact of screening FDR of DCM probands using a mobile ECG with the ability to transmit the ECG for cloud-based AI analysis to detect reduced left ventricular ejection…
- Trial name
- NCT06609174
- Testing
- KardiaRx ECG Screening and AI interpretation of ECG
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- Mayo Clinic
DMD-Associated Dilated Cardiomyopathy
Modulation of SERCA2a of Intra-Myocytic Calcium Trafficking in Cardiomyopathy Secondary to Duchenne Muscular Dystrophy
This research study is testing whether an experimental drug, called SRD-001, is safe and helps the weakened heart of patients with Duchenne muscular dystrophy (DMD) regain its ability to effectively pump blood to the rest of the…
- Trial name
- MUSIC-DMD (NCT06224660)
- Testing
- SRD-001
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Sardocor Corp.
Muscular Dystrophy, Dilated Cardiomyopathy
The Cardiovascular Genetic and Therapeutic Implications of Muscular Dystrophy
This study will have significant impact on muscular dystrophy patients as it promotes early screening for heart disease. With early identification, beneficial medical therapy can be started sooner, resulting in restoring and…
- Conditions
- Muscular Dystrophy, Dilated Cardiomyopathy, Heart Failure
- Trial name
- NCT00518817
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Baylor College of Medicine
Dilated Cardiomyopathy
Clinical and Genetic Examinations of Dilated Cardiomyopathy
This study is a descriptive study to investigate clinical and genetic features of dilated cardiomyopathy (DCM) patients and their relatives.
- Trial name
- NCT02148926
- Where
- Denmark
- Volunteers
- 554 people
- Sponsor
- University of Southern Denmark
Heart Failure, Congestive, Ventricular Dysfunction
Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Destination Therapy
The purpose of this study is to determine the safety and effectiveness of the Thoratec HeartMate II Left Ventricular Assist System (LVAS) as Destination Therapy in end-stage heart failure patients who do not qualify for cardiac…
- Conditions
- Heart Failure, Congestive, Ventricular Dysfunction, Cardiomyopathies
- Trial name
- NCT00121485
- Testing
- Left Ventricular Assist System (LVAS)
- Where
- 47 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Abbott Medical Devices